Abstract
Background
Accurate information on the facility costs of treatment is essential to enhance decision making and funding for malaria control.
Objective
The objective of this study was to estimate the costs of providing treatment for uncomplicated malaria through a public health facility in Nigeria.
Methods
Hospital costs were estimated from a provider perspective, applying a standard costing procedure. Capital and recurrent expenditures were estimated using an ingredient approach combined with step-down methodology. Costs attributable to malaria treatment were calculated based on the proportion of malaria cases to total outpatient visits. The costs were calculated in local currency [Naira (N)] and converted to US dollars at the 2013 exchange rate.
Results
Total annual costs of N28.723 million (US$182,953.65) were spent by the facility on the treatment of uncomplicated malaria, at a rate of US$31.49 per case, representing approximately 25% of the hospital’s total expenditure in the study year. Personnel accounted for over 82.5% of total expenditure, followed by antimalarial medicines at 6.6%. More than 45% of outpatients visits were for uncomplicated malaria. Changes in personnel costs, drug prices and malaria prevalence significantly impacted on the study results, indicating the need for improved efficiency in the use of hospital resources.
Conclusion
Malaria treatment currently consumes a considerable amount of resources in the facility, driven mainly by personnel cost and a high proportion of malaria cases. There is scope for enhanced efficiency to prevent waste and reduce costs to the provider and ultimately the consumer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Nnamdi Azikiwe University, Department of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, Awka, Nigeria (GRID:grid.412207.2) (ISNI:0000 0001 0117 5863)
2 Federal University of Minas Gerais, Pharmacy College, Belo Horizonte, Brazil (GRID:grid.8430.f) (ISNI:0000 0001 2181 4888)
3 Strathclyde University, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK (GRID:grid.11984.35) (ISNI:0000000121138138); Karolinska Institutet, Division of Clinical Pharmacology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); University of Liverpool Management School, Liverpool Health Economics Centre, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)





